Table 7.

Cost-consequence analysis of candesartan compared with placebo in the treatment of HF – clinical benefits and annual per patient saving/cost increase (95% CI)

Trial	Clinical benefits vs placebo	DRG costs	Per-diem costs
CHARM-Alternative	CV deaths (−15%) HF admission (−32%)	Net increase (€22 ± 245/year)	Savings (€291 ± 421/year)
CHARM-Added	CV deaths (−16%) HF admission (−17%)	Savings (€81 ± 214/year)	Savings (€267 ± 328/year)
CHARM-Preserved	CV deaths (−1%), ns HF admission (−15%)	Net increase (€249 ± 128/year)	Net increase (€249 ± 232/year)
CHARM-Overall	CV deaths (−12%) HF admission (−21%)	Net increase (€83 ± 111/year)	Savings (€56 ± 179/year)

Abbreviations: CV, cardiovascular; DRG, diagnosis related group; HF, heart failure.